Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency.
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
The hyperparathyroidism characteristic of patients with moderate renal insufficiency could be caused by decreases in the plasma concentration of ionized calcium (Ca++) evoked by: (a) recurring increases in the plasma concentration of inorganic phosphorus that may be detectable only in the post-prandial period; (b) a reversible, phosphorus-mediated suppression of renal 25-hydroxyvitamin D-1 alpha-hydroxylase that decreases the plasma concentration of 1,25-dihydroxyvitamin D (1,25-(OH)2D) enough to decrease both gut absorption and bone resorption of Ca++; (c) both of these. In a group of eight children with moderate renal insufficiency, mean glomerular filtration rate (GFR) 45 +/- 4 (SE) ml/min per 1.73 M2, ages 6-17 yr, we tested these hypotheses by determining the effect of short term (5 d) restriction and supplementation of dietary intake of phosphorus on the plasma concentration of 1,25-(OH)2D, the serum concentrations of immunoreactive parathyroid hormone (iPTH) and phosphorus, and the fractional renal excretion of phosphorus ( FEPi ). When dietary phosphorus was normal, 1.2 g/d, the serum concentrations of phosphorus throughout the day were not greater than those of normal control children, and the serum concentrations of carboxyl-terminal iPTH (C-iPTH) were greater, 59 +/- 9 vs. 17 +/- 3 mu leq/ml, and unchanging; the serum concentration of intact-iPTH was also greater, 198 +/- 14 vs. 119 +/- 8 pg/ml. The plasma concentration of 1,25-(OH)2D was lower than that of age-matched controls, 27 +/- 3 vs. 36 +/- 2 pg/ml (P less than 0.01). When dietary phosphorus was restricted to 0.35 g/d, the plasma concentration of 1,25-(OH)2D increased by 60% to a mean value not different from that of normal controls, while serum concentrations of C-iPTH and intact-iPTH decreased by 25%, the latter concentration to a mean value not different from that of controls. FEPi decreased from 31 to 9%. When dietary phosphorus was supplemented to 2.4 g/d, the plasma concentration of 1,25-(OH)2D decreased 32%, while those of C-iPTH and intact-iPTH increased by 131 and 45%, respectively; FEPi increased from 27 to 53%. Plasma concentrations of 25-hydroxyvitamin D remained normal and unchanged, and GFR did not change when dietary phosphorus was manipulated. The data demonstrate that in children with moderate renal insufficiency: (a) A normal dietary intake of phosphorus in attended by a decreased circulating concentration of 1,25-(OH)2D and an increased concentration of iPTH, but not by recurring increases in the serum concentration of phosphorus at any time of the day; (b) Dietary phosphorus is, however, a major determinant of the circulating concentrations of both 1,25-(OH)2D and iPTH, which vary inversely and directly, respectively, with dietary intake of phosphorus, and increase and decrease, respectively, to normal values when phosphorus is restricted for 5 d; (c) Restriction and supplementation of dietary phosphorus induces changes in the serum concentration of iPTH that correlate strongly but inversely with those induced in the plasma concentration of 1,25-(OH)2D (r = -0.88, P < 0.001); and (d) The physiologic responsiveness of the renal tubule to changes in dietary phosphorus is to a substantial extent intact. The data provide support for the second hypothesis stated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE COLORIMETRIC DETERMINATION OF PHOSPHORUS
Fiske, C. H., & Subbarow, Y. (1925) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)84756-1 · Cited by 18,997
Unique Biosynthesis by Kidney of a Biologically Active Vitamin D Metabolite
FRASER, D. R., & KODICEK, E. (1970) · Nature · doi:10.1038/228764a0 · Cited by 1,281
The control of 25-hydroxyvitamin D metabolism by inorganic phosphorus
Tanaka, Y., & Deluca, H. F. (1973) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(73)90010-6 · Cited by 780
Control of 25-Hydroxycholecalciferol Metabolism by Parathyroid Glands
Garabedian, M., Holick, M. F., Deluca, H. F., & Boyle, I. T. (1972) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.69.7.1673 · Cited by 668
Regulation of 25-Hydroxycholecalciferol-1-Hydroxylase Activity in Kidney by Parathyroid Hormone
FRASER, D. R., & KODICEK, E. (1973) · Nature New Biology · doi:10.1038/newbio241163a0 · Cited by 527
Eisman, J. A., Hamstra, A. J., Kream, B. E., & DeLuca, H. F. (1976) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(76)90161-2 · Cited by 512
On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog
Slatopolsky, E., Caglar, S., Pennell, J. P., Taggart, D. D., Canterbury, J. M., Reiss, E., & Bricker, N. S. (1971) · Journal of Clinical Investigation · doi:10.1172/jci106517 · Cited by 481
Regulation of Serum 1α,25-Dihydroxyvitamin D 3 by Calcium and Phosphate in the Rat
Hughes, M. R., Brumbaugh, P. F., Hussler, M. R., Wergedal, J. E., & Baylink, D. J. (1975) · Science · doi:10.1126/science.1188357 · Cited by 404
Determination of vitamin D and its metabolites in plasma from normal and anephric man
Shepard, R. M., Horst, R. L., Hamstra, A. J., & DeLuca, H. F. (1979) · Biochemical Journal · doi:10.1042/bj1820055 · Cited by 369
GRAY, R. W., WILZ, D. R., CALDAS, A. E., & LEMANN, J. (1977) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-45-2-299 · Cited by 318
Cited by
Bone metabolism and disease in chronic kidney disease
Eknoyan, G., Levin, A., & Levin, N. W. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00905-3 · Cited by 1,286
Gutierrez, O., Isakova, T., Rhee, E., Shah, A., Holmes, J., Collerone, G., Ju[Combining Diaeresis]ppner, H., & Wolf, M. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010052 · Cited by 921
The Vitamin D Epidemic and its Health Consequences
Holick, M. F. (2005) · The Journal of Nutrition · doi:10.1093/jn/135.11.2739s · Cited by 579
Moe, S. M., Zidehsarai, M. P., Chambers, M. A., Jackman, L. A., Radcliffe, J. S., Trevino, L. L., Donahue, S. E., & Asplin, J. R. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05040610 · Cited by 564
Slatopolsky, E., Finch, J., Denda, M., Ritter, C., Zhong, M., Dusso, A., MacDonald, P. N., & Brown, A. J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118701 · Cited by 511
Christakos, S., Ajibade, D. V., Dhawan, P., Fechner, A. J., & Mady, L. J. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.02.002 · Cited by 430
Dietary Phosphorus Regulates Serum Fibroblast Growth Factor-23 Concentrations in Healthy Men
Antoniucci, D. M., Yamashita, T., & Portale, A. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0021 · Cited by 421
Self-citationClinical Practice Guideline for the Management of Chronic Kidney Disease‐Mineral and Bone Disorder
Fukagawa, M., Yokoyama, K., Koiwa, F., Taniguchi, M., Shoji, T., Kazama, J. J., Komaba, H., Ando, R., Kakuta, T., Fujii, H., et al. (2013) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12058 · Cited by 402
Calcium Carbonate as a Phosphate Binder in Patients with Chronic Renal Failure Undergoing Dialysis
Slatopolsky, E., Weerts, C., Lopez-Hilker, S., Norwood, K., Zink, M., Windus, D., & Delmez, J. (1986) · New England Journal of Medicine · doi:10.1056/nejm198607173150304 · Cited by 379
Renal bone disease 1990: An unmet challenge for the nephrologist
Malluche, H., & Faugere, M.-C. (1990) · Kidney International · doi:10.1038/ki.1990.187 · Cited by 362
Hasegawa, H., Nagano, N., Urakawa, I., Yamazaki, Y., Iijima, K., Fujita, T., Yamashita, T., Fukumoto, S., & Shimada, T. (2010) · Kidney International · doi:10.1038/ki.2010.313 · Cited by 341
Bone tissue regeneration: biology, strategies and interface studies
Ansari, M. (2019) · Progress in Biomaterials · doi:10.1007/s40204-019-00125-z · Cited by 340
Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure
Hamdy, N. A. T., Kanis, J. A., Beneton, M. N. C., Brown, C. B., Juttmann, J. R., Jordans, J. G. M., Josse, S., Meyrier, A., Lins, R. L., & Fairey, I. T. (1995) · BMJ · doi:10.1136/bmj.310.6976.358 · Cited by 322
Vitamin D in chronic kidney disease: A systemic role for selective vitamin D receptor activation
Andress, D. L. (2006) · Kidney International · doi:10.1038/sj.ki.5000045 · Cited by 309
Forging Forward with 10 Burning Questions on FGF23 in Kidney Disease
Wolf, M. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009121293 · Cited by 308
Khundmiri, S. J., Murray, R. D., & Lederer, E. (2016) · Comprehensive Physiology · doi:10.1002/cphy.c140071 · Cited by 296
Metabolic Bone Disease in Chronic Kidney Disease
Martin, K. J., & González, E. A. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006070771 · Cited by 288
Portale, A. A., Halloran, B. P., Murphy, M. M., & Morris, R. C. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112304 · Cited by 273
Self-citationPatterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease
Pereira, R. C., Jűppner, H., Azucena-Serrano, C. E., Yadin, O., Salusky, I. B., & Wesseling-Perry, K. (2009) · Bone · doi:10.1016/j.bone.2009.08.008 · Cited by 272
Portale, A. A., Halloran, B. P., & Morris, R. C. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114043 · Cited by 269
Self-citationMechanisms and Regulation of Intestinal Phosphate Absorption
Hernando, N., & Wagner, C. A. (2018) · Comprehensive Physiology · doi:10.1002/cphy.c170024 · Cited by 70
Kägi, L., Bettoni, C., Pastor-Arroyo, E. M., Schnitzbauer, U., Hernando, N., & Wagner, C. A. (2018) · PLOS ONE · doi:10.1371/journal.pone.0195427 · Cited by 46
Metadata
- Authors
- Portale, A. A., Booth, B. E., Halloran, B. P., & Morris, R. C.
- Venue
- Journal of Clinical Investigation
- Published
- 1984-06-01
- Volume
- 73
- Issue
- 6
- Pages
- 1580-1589
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1979542010
- Cited by
- 353
- References
- 43
- FWCI
- 13.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.